Results 181 to 190 of about 9,805,880 (332)

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

British Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky, Stefan Engeli, Stefanie M. Bode‐Böger, Felix Koop, Martin Schulze Westhoff, Sebastian Schröder, Carsten Schumacher, Thorben Pape, Dirk O. Stichtenoth, Johannes Heck   +9 more
wiley   +1 more source

A real‐world data‐driven approach to optimizing enoxaparin dosing in burn patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Enoxaparin dosing in burn patients is challenging due to physiological changes affecting absorption, distribution and clearance. The objectives of this study are to develop a population pharmacokinetic (PK) model for enoxaparin in burn patients, evaluate target attainment with current equation‐based (EQ) dosing and propose an optimized dosing ...
Babajide Shenkoya, Venkata Yellepeddi, Ann Marie B. Prazak, Mathangi Gopalakrishnan   +3 more
wiley   +1 more source

Compass Rose: Providing Direction and Automation of Glomerular Disease Drug Monitoring. [PDF]

Kidney360
Bobart SA, Aslam N.
europepmc   +1 more source

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer

British Journal of Clinical Pharmacology, EarlyView.
Aims Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug–drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants.
Catharina J. P. Op 't Hoog, Niven Mehra, Anouk van Kleef, Diederik M. Somford, Inge M. van Oort, Alex L. T. Imholz, Paul Hamberg, Nielka P. van Erp, Emmy Boerrigter   +8 more
wiley   +1 more source

The effects of pregnancy on the progression of maternal glomerular disease. [PDF]

J Bras Nefrol
Marques LPJ, Salla LM, Rioja LDS, Rocco R, Madeira EPQ, Vieira LMSF.   +5 more
europepmc   +1 more source

Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease

Journal of Clinical Investigation, 2017
Syamantak Majumder, Karina Thieme, S. N. Batchu, Tamadher A. Alghamdi, Bridgit B. Bowskill, M. G. Kabir, Youan Liu, Suzanne L. Advani, K. White, L. Geldenhuys, Karthik K. Tennankore, Penelope Poyah, Ferhan S. Siddiqi, A. Advani   +13 more
semanticscholar   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

A Phenomenological Study of the Lived Illness Experience of Adolescents with Chronic Glomerular Disease. [PDF]

Children (Basel)
Lee SY.
europepmc   +1 more source

Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines.

American Society of Nephrology. Clinical Journal, 2017
K. Blom, A. Odutayo, K. Bramham, M. Hladunewich   +3 more
semanticscholar   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source